Hepatic AMPK activity has been identified as significantly associated with the prevalence of NAFLD, and activation of AMPK prevents NAFLD/NASH progression, including hepatic steatosis, fibrosis, and inflammation (33, 38). The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatohepatitis.